Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

X
Trial Profile

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Capecitabine; Carboplatin; Cisplatin; Eribulin; Gemcitabine; Paclitaxel
  • Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SOLARA
  • Most Recent Events

    • 02 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 May 2024.
    • 07 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2024.
    • 14 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Jan 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top